The Bufo Ceremony: What Happens, Who It Helps, and Who Should Not Proceed

A bufo ceremony uses vaporised 5-MeO-DMT — drawn either from the parotoid gland secretion of the Incilius alvarius toad or, more commonly now, synthesised in a laboratory — and produces a period of complete ego dissolution lasting 20 to 45 minutes. Most people who contact us about a bufo ceremony want to know whether it will help them. The more useful question is whether they are an appropriate candidate. Those are not the same question.

What is a bufo ceremony?

The name comes from Bufo alvarius — the toad now reclassified as Incilius alvarius, native to the Sonoran Desert of northern Mexico and the southwestern United States. The toad's parotoid glands secrete a substance containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), one of the most pharmacologically potent psychedelic compounds known. When dried and vaporised, the secretion produces an experience of complete ego dissolution within seconds of inhalation.

Many providers now use synthetic 5-MeO-DMT rather than toad-derived material. The active compound is chemically identical. The reasons for using synthetic are practical: wild toad collection raises conservation concerns, the Sonoran Desert toad is already under pressure from habitat loss and collection for ceremonial use, and synthetic production allows for more consistent dosing. At Transcend, we use synthetic 5-MeO-DMT.

The ceremony itself is simple in form: a facilitator prepares the vaporised compound, the participant inhales it, and the active experience begins within seconds. Duration runs 20 to 45 minutes of active pharmacological effect. The compound has a half-life of roughly 15 minutes in humans. What happens in those 20–45 minutes is not simple.

What happens during the ceremony

Within seconds of inhalation, most people lose their sense of individual self — not partially, but completely. The experience 5-MeO-DMT produces is not primarily visual. It is not narrative. It is, for the majority of participants, a dissolution of the boundary between self and not-self. The structure of ordinary experience — subject, object, time — does not hold in its usual form. Most people cannot form or retain memories during the peak.

The peak typically lasts 10–20 minutes. Recovery from acute pharmacological effects takes 45–90 minutes in total. Many participants feel emotionally open, disoriented, or raw in the hours following. Some report a sustained sense of stillness or relief. Others feel unsettled. Some feel nothing in particular — the integration period is what gives the experience its meaning, if it has any.

There is no typical content. No standard vision, no predictable message, no narrative arc the experience reliably follows. 5-MeO-DMT produces something more like a total interruption of ordinary processing than a guided journey. People who arrive with specific expectations — for an insight, a revelation, a particular experience — tend to find the disruption of those expectations the most disorienting aspect.

The ceremony requires a facilitator present throughout. Participants may make sounds, move involuntarily, or have difficulty returning to ordinary verbal communication for some time after the peak. This is not a ceremony that can be safely conducted without trained facilitation in the room. For a more detailed account of what participants report, see the phenomenology of the bufo experience.

Shorter is not easier — the intensity misconception

People researching bufo ceremony alongside ibogaine sometimes describe 5-MeO-DMT as the easier or lighter option because it is shorter. This is a misunderstanding worth addressing directly.

5-MeO-DMT is not a lighter version of ibogaine. It is shorter, not easier. The intensity of complete ego dissolution in 20–45 minutes produces its own demands. Ibogaine lasts 12–24 hours and produces biographical content — memories, themes, specific material that can be worked with directly in integration. 5-MeO-DMT produces complete ego dissolution with no narrative content. There is nothing to decode. There is only the encounter with the total absence of self, and then the return.

The absence of narrative content does not make integration easier — it makes it different, and for many people harder. You have had an experience that cannot be described in the usual terms, and integration involves returning to ordinary life with something that has no story attached to it. Some people find 5-MeO-DMT easier than ibogaine. Others find it significantly harder. Duration is not the relevant variable.

This matters for candidacy. If someone is researching bufo ceremony specifically to avoid the difficulty of ibogaine, that reasoning may not hold. The conversation worth having is which medicine is appropriate for what you are working with — not which one is shorter. The comparison of 5-MeO-DMT and ibogaine covers the distinctions in more detail.

What the current evidence shows

The evidence base for 5-MeO-DMT in humans is growing but less developed than what exists for ibogaine or psilocybin. What exists is consistent in direction.

A 2019 survey study published in Frontiers in Psychology examined reports from 362 individuals who had used 5-MeO-DMT in naturalistic settings. Respondents reported significant improvements in depression, anxiety, and general wellbeing in the weeks following. Mystical experiences — rated using validated scales — were the strongest predictor of positive outcomes. The study was observational and the population self-selected; the results reflect reported experiences, not clinical measurements.

A 2018 study published in Psychopharmacology documented that a group 5-MeO-DMT session produced improvements in self-rated wellbeing and life satisfaction that persisted at four-week follow-up. The same limitations apply: observational, no control group.

5-MeO-DMT is not where ibogaine is in terms of the clinical evidence pipeline. The research exists and is building. Anyone who presents the observational data as equivalent to controlled trial evidence is overstating it. Anyone who dismisses it entirely because it does not come from RCTs is ignoring a consistent signal. The honest position is that the direction is clear and the evidence is preliminary.

Who bufo ceremony may help

Based on observational evidence and practitioner reports — not controlled trials — the populations who most frequently seek and report meaningful outcomes from 5-MeO-DMT ceremony include:

• People with treatment-resistant depression who have not found adequate relief through conventional approaches and have not responded to psilocybin or ketamine
• People working with PTSD, particularly those for whom narrative processing in therapy has been unproductive or retraumatising
• People dealing with existential distress — questions of meaning, mortality, and identity — rather than a specific psychiatric diagnosis
• People who have already completed an ibogaine ceremony and full integration cycle and are using 5-MeO-DMT as a complementary practice
• People with a stable foundation — no active psychiatric crisis, no contraindicated medications — who are approaching the work with preparation rather than desperation

Who bufo ceremony does not help: people in acute psychiatric crisis, people taking contraindicated medications who cannot safely taper before ceremony, people with a history of psychosis, and people seeking the experience primarily for its content — a specific revelation or insight — rather than the encounter itself.

Who cannot proceed — absolute contraindications

The following conditions are absolute contraindications for 5-MeO-DMT ceremony. No case is an exception.

SSRIs and SNRIs. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors must be fully cleared before any 5-MeO-DMT ceremony. The risk is serotonin syndrome — a potentially fatal condition. SSRIs and SNRIs are not contraindicated because providers prefer you not take them. They are contraindicated because the combination can kill you. The taper timeline depends on the specific medication. Fluoxetine has a significantly longer half-life than other SSRIs and may require 4–6 weeks or more after the final dose. This taper must be supervised by the prescribing physician.

MAOIs. Monoamine oxidase inhibitors — including the beta-carbolines found in ayahuasca — interact with 5-MeO-DMT to dramatically amplify and extend its effect. The combination is dangerous. If you have used ayahuasca recently, a minimum of two weeks must elapse after the last ceremony before 5-MeO-DMT is appropriate; four weeks is the more conservative window most providers use.

Antipsychotics and lithium. Current antipsychotic use and lithium are absolute contraindications. Lithium specifically has been associated with spontaneous seizures in the context of psychedelic compounds. The combination of lithium and 5-MeO-DMT is contraindicated regardless of dose or duration of lithium use.

Personal or family history of psychosis or schizophrenia. A personal history of psychosis — or a first-degree family member with schizophrenia — is a contraindication. The experience of complete ego dissolution in someone with psychosis vulnerability can trigger an acute psychotic episode.

Significant cardiovascular conditions. 5-MeO-DMT produces a transient but sharp increase in heart rate and blood pressure at the onset of the experience. Severe hypertension, arrhythmia, and significant cardiac disease require physician assessment before any decision about candidacy.

Pregnancy. No ceremony is appropriate during pregnancy.

Acute psychiatric instability. Someone in active crisis — acute suicidality, recent psychiatric hospitalisation, active psychotic symptoms — is not an appropriate candidate. The experience amplifies what is present. It does not stabilise it.

The screening conversation that ends in a no is one of the most important things any legitimate provider does. People in crisis who have found a thread of hope do not receive a no easily. Delivering it clearly, without cushioning, is an act of care — not rejection. The overview of what a bufo ceremony involves covers the general programme structure at Transcend.

What a legitimate programme includes

Before attending any bufo ceremony, the question worth asking is not what will I experience, but what infrastructure is in place for what might go wrong.

A legitimate bufo ceremony programme includes:

• A medical intake process reviewed by a physician or nurse practitioner familiar with 5-MeO-DMT contraindications — not a form that asks your age and nothing else
• Explicit screening for all medications (including supplements and herbal compounds that can interact), psychiatric history, and cardiovascular history
• A direct no when screening determines the person is not an appropriate candidate — not a waiver, not a disclaimer, not proceed at your own risk
• At least one facilitator trained in psychological support for difficult experiences, physically present throughout the active period
• A supervised recovery period in the hours following ceremony
• Clear integration resources — either in-house or clearly referred — for the weeks following the experience

Facilitators who accept applications without a screening conversation are not providing safe ceremony. They are providing access to a powerful compound without the infrastructure to identify who should not be in the room. For what the programme at Transcend specifically includes, see the 5-MeO-DMT retreat guide.

Cost in Vancouver, BC

A bufo ceremony at Transcend in Vancouver, BC costs $600–$1,500 CAD. The range reflects individual medical circumstances and whether the person is attending for a standalone 5-MeO-DMT ceremony or as part of a combined ibogaine and 5-MeO-DMT programme. It is not a tiered amenity model.

The cost covers the medicine, facilitation, the pre-ceremony screening conversation, and the supervised recovery period. Integration coaching is a separate service at $150–$300 CAD per session. It is not included in the ceremony cost, and it is not optional for people who want the ceremony to produce lasting change.

If you are comparing providers on price, ask specifically what each price point includes and excludes. Providers at the low end of the range have typically removed adequate screening, qualified facilitation, or integration support — or all three.

Integration — the period that determines the outcome

The active pharmacological experience is 20–45 minutes. The integration period is months.

The pattern that produces the least satisfying outcomes is consistent: the ceremony was significant, the person left with a sense of something having shifted, and they returned immediately to the environment, relationships, and unaddressed conditions that were producing the difficulty in the first place. Six weeks later, the sense of shift had faded. The contrast — between what seemed possible during and immediately after ceremony and what they had returned to — was sometimes sharper than before the ceremony, which made the disappointment more acute.

This is not a failure of the medicine. It is a predictable consequence of treating the ceremony as the endpoint rather than the beginning.

Integration for 5-MeO-DMT does not follow the same path as integration for ibogaine. Ibogaine produces biographical content — memories, themes, material with a narrative — that can be worked with in a relatively structured way. 5-MeO-DMT produces an encounter with formlessness. There is no content to process in the conventional sense. Integration involves returning to ordinary life with something that cannot be described, and noticing how it changes the texture of ordinary experience over time. That is harder than it sounds, and it benefits from working with someone who has guided the process before. The integration after plant medicine guide covers what that looks like in practice.

If you attend a bufo ceremony and then return to your life without any integration structure in place, the probability of the experience producing lasting change is lower than if you had prepared for the integration period before the ceremony. This is not something to figure out afterward.

Frequently asked questions